Q-omics provides the consensus-scored MEG3 profile across patient tissues and cancer cell-line models. MEG3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MEG3 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MEG3 RNA expression shows 17,349 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, BLCA, and BRCA as cancer lineages where MEG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEG3 survival associations across molecular data types. MEG3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEG3 RNA expression–survival associations across cancer types. High MEG3 expression shows unfavorable associations in KIRP, KIRC, CESC and STAD, but favorable associations in UCS and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for MEG3 RNA expression.
This table summarizes MEG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MEG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEG3 shows lower tumor expression in BLCA, KIRP, KIRC, KICH, UCEC and BRCA. The BLCA box plot shows higher MEG3 RNA expression in normal versus tumor tissue (log2 FC = −1.837, t-test p < 0.001).
This table shows molecular features associated with MEG3 in patient tissues and cancer cell lines. In patient samples, MEG3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
